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Abstract
Background: The genetic origins of chemotherapy resistance are well established; however, the role of epigenetics
in drug resistance is less well understood. To investigate mechanisms of drug resistance, we performed systematic
genetic, epigenetic, and transcriptomic analyses of an alkylating agent-sensitive murine lymphoma cell line and a
series of resistant lines derived by drug dose escalation.
Methods: Dose escalation of the alkylating agent mafosfamide was used to create a series of increasingly drug-
resistant mouse Burkitt’s lymphoma cell lines. Whole genome sequencing, DNA microarrays, reduced representation
bisulfite sequencing, and chromatin immunoprecipitation sequencing were used to identify alterations in DNA
sequence, mRNA expression, CpG methylation, and H3K27me3 occupancy, respectively, that were associated with
increased resistance.
Results: Our data suggest that acquired resistance cannot be explained by genetic alterations. Based on integration
of transcriptional profiles with transcription factor binding data, we hypothesize that resistance is driven by epigenetic
plasticity. We observed that the resistant cells had H3K27me3 and DNA methylation profiles distinct from those of the
parental lines. Moreover, we observed DNA methylation changes in the promoters of genes regulated by E2a and
members of the polycomb repressor complex 2 (PRC2) and differentially expressed genes were enriched for targets of
E2a. The integrative analysis considering H3K27me3 further supported a role for PRC2 in mediating resistance. By
integrating our results with data from the Immunological Genome Project (Immgen.org), we showed that these
transcriptional changes track the B-cell maturation axis.
Conclusions: Our data suggest a novel mechanism of drug resistance in which E2a and PRC2 drive changes in
the B-cell epigenome; these alterations attenuate alkylating agent treatment-induced apoptosis.
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Background
Many anticancer therapies lose effectiveness over time as
tumors acquire resistance. Despite significant study [1],
acquired resistance remains a major obstacle to improving
remission rates and achieving prolonged disease-free sur-
vival. A number of explanations for resistance have been
proposed, including the presence of cancer stem cells [2]
and mutations that confer drug resistance [3].
Although Burkitt’s lymphoma is extremely aggressive
[4], 90–95 % of children receiving the standard-of-care
therapy, a combination treatment of rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisone,
enter complete remission. Treatment of adults is not as
successful [5], in part due to acquired resistance. In both
children and adults, salvage treatment has a poor suc-
cess rate, with only one-third of children and very few
adults obtaining positive outcomes from salvage therapy.
The mechanisms underlying acquisition of resistance in
Burkitt’s lymphoma are only partially understood. Numer-
ous genetic mechanisms have been hypothesized, including
up-regulation of expression of proteins involved in drug ef-
flux, such as the ATP-binding cassette transporter family,
cyclophosphamide inactivation through aldehyde dehydro-
genase up-regulation, increased expression of DNA repair
enzymes, and deregulation of apoptosis through the loss of
Tp53 [1]. Genetic mutations are unable to explain cases of
acquired resistance that arise rapidly or that reverse in re-
sponse to a drug holiday [6, 7].
Alterations in histone modifications and DNA methy-
lation that lead to an altered transcriptional program
have been proposed to lead to acquired drug resistance
in B-cell lymphoma [8, 9]. Recent work in an in vitro
model of Burkitt’s lymphoma has shown that treatment
with the DNA methylation inhibitor 5-azacytidine reacti-
vates expression of Id2, which encodes a repressor of
translocated Myc, resulting in the inhibition of prolifera-
tion [10]. Similarly, treatment of lymphoma cell lines
with the histone deacetylase inhibitor suberoylanilide
hydroxamic acid has been shown to re-sensitize lymph-
oma cell lines to various therapeutic agents [11].
Studies of clinical specimens have revealed that tu-
mors are both genetically and epigenetically heteroge-
neous [8, 12]. The role of genetic heterogeneity within
tumors and its effect on treatment response and out-
come has been extensively studied, but less is known
about how epigenetic heterogeneity impacts disease
progression and clinical outcome. Previous studies have
shown that drug treatment generates selective pressure on
heterogeneous populations that leads to the enrichment of
specific genetically distinct subpopulations [13, 14]. These
subpopulations can ultimately become the dominant popu-
lation in a tumor, resulting in resistance to the therapeutic
agent. It is possible that similar mechanisms of selection
act at the epigenetic level. Recent research in prostate
cancer has documented the inherent heterogeneity of
DNA methylation in patient tumor samples [15], though
the selection of epigenetically distinct subpopulations has
yet to be shown.
Here we used dose escalation with mafosfamide on
parental Eμ-Myc Cdkn2a-/- non-Hodgkin’s B-cell lymph-
oma cells to generate a series of drug-resistant cell lines.
We then investigated the mechanism by which these
cells acquired resistance. In our experiment, parental
cells were cultured with increasing doses of mafosfa-
mide, from 100 nM to 4 μM, over 5 weeks. At four steps
in the dose escalation, resistant clones were isolated and
molecularly profiled. Whole-genome sequencing of the
parental and resistant cell lines did not reveal any gen-
etic alterations that might explain the acquired resist-
ance. However, analyses of transcriptomic and DNA
methylation profiling suggested that the acquired resist-
ance is associated with genes and promoters targeted by
transcription factor E2a and by members of the poly-
comb repressive complex 2 (PRC2), Suz12 and Pcl2. An
integrative analysis considering histone H3 lysine 27 tri-
methylation (H3K27me3) further supported a role for
PRC2 in mediating resistance. Comparison of the tran-
scriptomic data from resistant lines and from B cells at
different developmental stages [16] suggested that resist-
ance is associated with epigenetic changes that are found
along the B-cell maturation axis. E2a is a master regula-
tor of B-cell development in mice. An analysis of human
diffuse B-cell methylation data revealed that the methy-
lation status of genes regulated by the human ortholog
of E2a, TCF3, is associated with treatment failure. Thus,
our study implicates epigenetic factors in evolution of
acquired resistance.
Methods
Creation of resistant Eμ-Myc Cdkn2a-/- lines
The parental Eμ-Myc Cdkn2a-/- lymphoma line was gener-
ated from a C57BL/6 J mouse as described in Schmitt et al.
[17]. Lymphoma cells from these mice were cultured in
vitro to generate the cell line. Resistant strains were gener-
ated from this parental line via dose escalation from 100
nM to 4 μM of mafosfamide (Cell Signaling Technology)
over a 34-day period.
Cell viability and cell cycle analysis
Cell viability was measured using the Perkin-Elmer
Operetta platform with 2.5 μM Draq5 (Abcam) for nu-
clear detection and 5 μg/mL of propidium iodide
(Sigma-Aldrich, St. Louis, MO, USA) to detect dead
cells. For cell cycle analysis, cells were fixed in ethanol
and placed in solution with propidium iodide. Cells
were gated for G0/G1, S, and M phase on a Beckman
LSRII.
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Genome sequencing
Genomes of cell lines were sequenced to a minimum of 8×
average coverage using Illumina HiSeq 2000 sequencers.
The reads were aligned to the mm9 (MGSCv37) Mus mus-
culus reference genome using BWA version 0.6.2-r126
(backtrack) [18] with default parameters. Duplicate reads
were removed using PICARD version 1.85(1345) with
default parameters (Additional file 1). The whole-genome
sequencing data are available via the Sequence Read Arch-
ive under accession number SRP071753.
Oligonucleotide microarray analysis
Oligonucleotide microarray analysis was carried out using
Affymetrix GeneChip Mouse Gene ST 1.0. The resulting
data are publically available via Gene Expression Omnibus
accession GSE60342. Data were quantified and processed
with robust multi-array averaging using the justRMA
function of the 1.40.0 affy R package [19]. Expression
values were log2 transformed for further downstream ana-
lysis. Probe sets were annotated using the Affymetrix
MoGene-1_0-st-v1.na33.2.mm9.probeset.csv file. We se-
lected the top 1000 probe sets ranked by their covariance
to identify differentially regulated genes (Additional file 1).
Transcription factor analysis
Targets for 64 murine transcription factors were identi-
fied from ChIPBase (http://deepbase.sysu.edu.cn/chip-
base, downloaded August 1, 2013) [20] and limited to
genes with binding events within 5 kilobases (kb) of
transcriptional start sites. To identify potential up-
stream regulators, we identified the overlap of chroma-
tin immunoprecipitation-sequencing (ChIP-seq) data
with predicted transcription factor targets and used a
one-sided Fisher’s exact test to determine significance.
ChIP-seq
Chromatin was immunoprecipitated as described previ-
ously [21]. Briefly, cells were grown to 50 % confluency.
Formaldehyde was added for 10 min at room temperature
and 100 μl of the lysate (5 × 106 cells) was used for each
immunoprecipitation with anti-H3K27me3 (Active Motive,
catalogue number 39155). Libraries were sequenced using
an Illumina HiSeq 2000 to obtain 50-bp-long reads.
Peaks were called by comparing counts in the immuno-
precipitated libraries with input libraries in windows tiling
the genome using Poisson statistics as previously described
[21]. Combinatorial clustering of data was achieved by
determining significant enrichment for the histone mark in
each condition within 5 kb upstream of transcription start
sites (at least three 50-bp bins with p < 1.0e-6). A binary
distribution was created based on a promoter being
enriched (1) or not enriched (0) and a combinatorial
matrix was created with all possible combinations across
all conditions. H3K27me3 data were plotted based on the
combinatorial clustering and visualized by a Cluster 3.0-
generated CDT file loaded on Java-Tree view to produce a
heat map. The ChIP-seq datasets are publically available
via Gene Expression Omnibus accession GSE78939.
Bisulfite sequencing
Reduced representation bisulfite (RRBS) libraries were
generated following the standard RRBS protocol [22]. The
genome was digested with the methylation-insensitive re-
striction enzyme MspI and fragments from 100 to 300
bases were selected. The fragments were ligated with Illu-
mina adaptors, denatured, and treated with sodium bisul-
fite. The libraries were sequenced using Illumina HiSeq
2000 sequencers. The reads were aligned using the bisul-
fite aligner BS Seeker2 [23] to determine where fragments
uniquely mapped allowing for three mismatches to the
reference genome (mouse mm9). The RRBS datasets are
publically available via Gene Expression Omnibus acces-
sion GSE78939.
DNA methylation analysis
To identify DNA methylation changes correlated with
resistance, we computed RRBS fragment CpG methyla-
tion levels and calculated the covariance between the
fragment methylation score and sample order (ordered
from least to most resistant; Additional file 1).
Principal component analysis
Principal component analysis of expression profiles was
performed by applying the R prcomp function with the
scaled option to the expression microarray values of the
resistant cell lines and B cells at different stages of devel-
opment (NCBI Gene Expression Omnibus accession
GSE15907). See Additional file 1 for samples used.
Results
Generation of resistant lines and assessment of cell cycle
characteristics
To investigate the factors driving acquisition of resist-
ance to chemotherapy, we employed a widely used cell
line derived from an Eμ-Myc mouse model of Burkitt’s
lymphoma [17]. We refer to this line as our “parental”
line. This model has two genetic alterations: (1) a trans-
location in the c-Myc oncogene that causes its expression
to be controlled by an immunoglobulin heavy chain en-
hancer, thus restricting its expression to B cell lineage
cells; and (2) a deletion in Cdkn2a that recapitulates a
common mutation seen in human tumors [24]. Eμ-Myc
Cdkn2a-/- mice develop lymphomagenesis with highly in-
vasive tumors with apoptotic defects [17]. Resistant lines
were generated by gradually exposing the parental line to
increasing concentrations from 100 nM to 4 μM of mafos-
famide (an in vitro active form of cyclophosphamide) in
cell culture (Fig. 1a, b; Additional file 1: Figure S1). Four
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resistant sub-clones were isolated during the 5-week period
of dose escalation (R100, R500, R1000, and R4000) for sub-
sequent analysis. We refer to these as the “resistant” lines.
The cycling rate of our parental and resistant lines in the
absence of mafosfamide was very similar (Additional file 1:
Table S1, Figure S2), suggesting that the resistance is not
associated with large changes in cell cycle phases.
Mafosfamide treatment led to a greater percentage of
apoptotic cells in the parental line relative to the resistant
lines (Fig. 1b; Additional file 1: Table S1, Figures S1 and S2).
In all lines, non-apoptotic cells showed an equivalent cell
cycle delay as assessed by the decrease in percentage of cells
in G1 and a concurrent increase in G2 percentage upon
treatment. As all the lines showed approximately the same
amount of cell cycle delay upon treatment in the non-
apoptotic fraction, resistance is most likely not a result of an
increased cell cycle delay.
Resistance is unlikely to have arisen by genetic mechanisms
Given the four-fold difference in drug sensitivity be-
tween the parental and resistant cell lines (parental half
maximal effective concentration, EC50, 857 ± 68 nM;
R4000 EC50 3446 ± 138 nM, mean ± standard error of
the mean), we initially hypothesized that acquired resist-
ance was mediated by genetic variants that were
enriched in the population over the course of the dose
escalation. To identify possible resistance-associated var-
iants, we performed whole-genome sequencing and
identified single-nucleotide variants (SNVs) that showed
an increase in allele frequency that correlated with in-
creased resistance. Twenty-three SNVs displayed this
pattern (Additional file 1: Figure S3). Of these, 13 had
variant alleles in only one sample (the most resistant
line) and manual inspection of read alignments showed
that the SNVs all occurred solely at the ends of sequen-
cing reads or in repetitive regions (Additional file 1:
Table S2) and were, therefore, likely sequencing artifacts.
To validate that these were in fact false positives, we per-
formed Sanger sequencing on regions surrounding five of
the potential SNVs. No mutations were observed using
this sequencing technique (Additional file 1: Figure S4).
Additionally, no novel large structural variations or poten-
tial copy number variations were found in any of the lines.
Together, these data suggest that genetic alterations are
not the principal explanation for the acquired resistance.
Alterations in gene expression of mafosfamide-resistant
cell lines
To determine whether the decreased sensitivity to mafosfa-
mide observed in the resistant lines was associated with al-
tered transcription, we measured the changes in gene
expression for the parental and each resistant line. A subset
of these gene expression changes were confirmed by quan-
titative PCR (Additional file 1: Figure S5). We expected to
identify genes known to be involved in drug metabolism,
transport of mustard alkylating agents, and DNA repair
[25, 26]. We found that the expression of most genes
involved in these processes did not increase signifi-
cantly in our resistant lines, suggesting that none of
these processes are likely to play a major role in medi-
ating resistance (Additional file 1: Figure S6).
To identify transcripts with expression patterns that
were perturbed with increasing resistance, we com-
puted the covariance of the expression of each gene
with the EC50 of the resistant cell line. The 1000 genes
with highest and lowest covariance were clustered
(Fig. 2a). Pathway analysis of those genes that showed a
positive covariance with resistance (i.e., an increase in
gene expression with increasing resistance) indicated
that they encode proteins involved in B-cell maturation
and development (Fig. 2b). Genes that showed a nega-
tive covariance were enriched for those associated with
EIF2-mediated signaling and T helper cell differenti-
ation (Fig. 2c).
Fig. 1 Dose escalation of Eμ-Myc Cdkn2a-/- cells and resistance to
mafosfamide. a Eμ-Myc Cdkn2a-/- cells were cultured with increasing
doses of mafosfamide. After 10, 18, 23, and 37 days, corresponding
to cells cultured in 100, 500, 1000, and 4000 nM of mafosfamide,
surviving cells were harvested. b The percentage viability of the
resistant cells was measured after 24-h exposure to mafosfamide
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DNA methylation changes with drug resistance
DNA methylation is a central mechanism of transcrip-
tional regulation and alterations in the methylome have
previously been shown to contribute to lymphomagene-
sis and drug resistance [27–29]. To gain further insights
into epigenetic changes that occurred during the acquisi-
tion of drug resistance, we measured DNA methylation
using reduced representation bisulfite sequencing
(RRBS) of the parental and resistant lines. This approach
allowed us to quantify the methylation of approximately
one million CpGs. To identify methylation sites associ-
ated with drug resistance, we computed the covariance
between the methylation state of each CpG and the EC50
of the resistant cell line. Covarying sites were clustered
(Fig. 3a). High covariance RRBS fragments had lower
levels of gene expression compared with overall expres-
sion based on all annotated probes, whereas low covari-
ance RRBS fragments had higher levels of gene
expression (Additional file 1: Figure S7). The top 1000
high covariance RRBS fragments were located in gene
regions that were functionally enriched for DNA bind-
ing, transcription factor activity, and cell differentiation
(Additional file 1: Table S3).
We next asked whether the genes that were proximal
to these sites were associated with specific transcription
factors. Each transcription factor from ChIPBase [20]
was tested for association with the 1000 genes with the
highest and lowest DNA methylation covariance with
respect to resistance (Fig. 3b). From this analysis, we
identified the transcription factors E2a and PU.1; these
transcription factors are involved in B-cell development
[30–33]. We also found that members of the polycomb
repressive complex 2 (PRC2) Suz12 and Pcl2 were very
strongly enriched over positively covarying genes, sug-
gesting an involvement of this complex in mediating epi-
genetic changes during the acquisition of drug
resistance. The expression of PRC2 members was similar
in parental and resistant lines; however, Uty, which en-
codes one of three known histone H3 lysine 27
demethylases [34], was down-regulated in the resistant
lines, suggesting that Uty may be involved in the epige-
nome alteration that confers drug resistance (Additional
file 1: Figure S8a, b).
Resistant cell lines show altered H3K27me3 occupancy
As PRC2 has been shown to be involved in placement of
the H3K27me3 mark [35], we performed ChIP-seq for
H3K27me3 in all lines (grown in the absence of mafosfa-
mide) to verify the involvement of PRC2 in the transition
to drug resistance. We found widespread acquisition of
H3K27me3 at the transcriptional start sites of a large
group of genes in the least resistant (R100, R500) lines
(Fig. 4a). These effects appeared to be stable across bio-
logical replicates, as seen by the high correlation between
replicate profiles (Additional file 1: Table S4). However,
the lines with increased resistance (R1000, R4000) had
Fig. 2 Microarray expression profile of untreated cell lines. a Heat map of the probe sets. Positive covariance with increasing resistance to mafosfamide is
indicated by the red cluster; negative covariance with resistance is indicated by the blue cluster. b The top 15 pathways enriched in negative covariance
genes. c The top 15 pathways enriched in positive covariance genes
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decreased levels of H3K27me3 with respect to the paren-
tal line at many loci.
As most H3K27me3 peaks are near the transcription
start sites, we analyzed promoters by means of combina-
torial clustering (described in “Methods”) and identified
three major groups of genes: those with a high level of
H3K27me3 throughout the time course (K1), those with
rapid and widespread H3K27me3 acquisition followed
by a gradual decrease (K2), and those with little to no
H3K27me3 (K3). Functional analysis of these groups
showed enrichment for developmentally regulated genes
in K1 and cell cycle-regulated genes in K2 (Fig. 4b, c).
The level of H3K27me3 across all genes bound by E2a
revealed that the average profile followed a similar pat-
tern of change to that of cluster K2 (Fig. 4d). Further-
more, E2a-bound genes were enriched in cluster K2 and
were depleted from K1 (Fig. 4e). These results suggest
that H3K27me3 occupancy may regulate expression of
E2a-bound genes.
Previously published literature shows a linkage between
Ezh2-mediated H3K27 methylation and DNA methyla-
tion. Ezh2 is the catalytic subunit of PRC2. Analysis of our
RRBS data revealed that DNA methylation levels prox-
imal to K2 genes increased between the parental and
resistant cell lines (Additional file 1: Figure S9a); we did
not observe an increase in DNA methylation in genes
in K1 or K3 subsets compared with parental levels
(Additional file 1: Figure S9b, c). Additionally, we found a
significant overlap between the high covariance RRBS
fragments and the K1 and K2 clusters (Additional file 1:
Figure S10). These results suggest a linkage between
H3K27me3 and DNA methylation at loci with altered ex-
pression during acquisition of resistance.
Principal component analysis of basal gene expression
indicates alterations in B-cell maturation
The observation that changes in expression, DNA
methylation, and H3K27me3 levels in the resistant
lines involve genes that encode regulators of B-cell de-
velopment (e.g., E2a and PU.1) led us to hypothesize
that gradual dose escalation results in epigenetic
changes associated with a B-cell maturation axis. To
identify the transcriptional profile characteristic of the
B-cell maturation axis, we used the Immunological
Genome Project (Immgen.org) dataset [36], which con-
tains expression data collected from B-cell progenitors,
cells at multiple stages during maturation, and mature
B cells.
To associate our expression data with the B-cell de-
velopmental axis, we performed a combined principle
component analysis of gene expression data obtained
from parental and resistant cell lines and B cells at
different stages of development gathered from the
Immgen dataset. We found that the second principal
Fig. 3 DNA methylation analysis. a Heat map of the top and bottom 1000 RRBS fragments based on covariance. b Heat map of the –log10(p) values
for the overlap of high and low covariance genes with transcription factor targets
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component, PC.2, captures the developmental state of
B cells (Fig. 5a) with less differentiated progenitor cells
toward the negative direction of the PC.2 axis and the
more mature states in the positive. Our four resistant
lines are ordered by their differentiation, with the least
resistant line more differentiated than the most resist-
ant line. This result suggests that the transcriptomes of
our cells vary monotonically along this B-cell develop-
mental axis. Additionally, functional annotation of the
top principal component genes showed enrichment for
the B-cell receptor signaling pathway in the top 1000
PC.2 genes (Additional file 1: Table S5).
To identify factors associated with this B-cell develop-
mental axis, we identified genes that had a positive cor-
relation with development (i.e., an increase in expression
during differentiation). We then used ChIPBase data to
identify factors with targets enriched within this list.
Genes positively correlated with development were often
targets of E2a and PU.1 (Fig. 5b).
Differential methylation status of E2a target genes is
associated with treatment failure in patients with
aggressive B-cell lymphoma
To confirm that E2a mediates resistance development, we
sought to determine the methylation status of genes
bound by TCF3, the human ortholog of E2a, in a clinically
relevant dataset. We obtained DNA methylation data
from diffuse large B-cell lymphoma (DLBCL) patients col-
lected from the Cancer Genome Atlas project. DLBCL dif-
fers from Burkitt’s lymphoma but is the most similar
lymphoma for which we were able to access data on clin-
ical samples.
Of 19 DLBCL samples available, 14 corresponded to pa-
tients who were tumor-free after their initial treatment
course and five were from patients who experienced disease
progression. For all methylation sites, we computed the
Kolmogorov–Smirnov statistic and an associated p value
between these two groups. From 482,421 total CG sites on
the Illumina 450 K array, 5541 had a Kolmogorov–Smirnov
Fig. 4 H3K27me3 ChIP-seq analysis. a Clusters of promoters based on their H3K27me3 levels in the parental and resistant lines (n = 2). TSS transcription
start site. b Group K1 shows enrichment for developmental genes. GO gene ontology. c Group K2 shows enrichment for cell cycle-regulated genes.
d Average H2K27me3 levels across E2a-bound genes. e Analysis of E2a-bound genes in the three clusters
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test with p < 0.05. We linked CpG sites to TCF3 binding re-
gions if both the CpG and binding region occurred within
the gene body or within 10 kb of the gene’s transcription
start site. We then identified the intersection of genes that
had both evidence of TCF3 binding and at least two CpG
sites with significant methylation changes between the two
patient populations. From a total of 17,744 genes used in
the linking calculations, we derived Table 1, which shows a
strong enrichment of TCF3-bound genes associated with
differentially methylated sites (p value ≤ 0.0001). This ana-
lysis suggests that TCF3-bound genes are differentially
methylated and are associated with treatment failure in a
lymphoma subtype.
To further test the clinical significance of differential
methylation, we compared lists compiled from our gene
expression and DNA methylation analyses with a 1458-
gene signature of DLBCL survival obtained from the
Precog data set [37]. Fifty-eight genes from the top 449
high expression covariance gene list and an additional
58 genes from the top 597 high methylation covariance
significantly overlapped with the 1458 genes associated
with DLBCL survival (p = 0.0001 and p = 0.0006, respect-
ively; Additional file 1: Figure S11a, b). Furthermore, those
genes that overlap between our H3K27me3 cluster K1 and
the high covariance RRBS fragments (Additional file 1:
Figure S10) similarly significantly overlapped with the
1458 genes associated with DLBCL survival (Additional
file 1: Figure S11c).
Discussion
By treating Eμ-Myc Cdkn2a-/- cells with escalating doses
of mafosfamide, we developed four cell lines with in-
creasing resistance to the drug. We hypothesized that if
a mutation provided a proliferative or survival advan-
tage, then the frequency of that mutation would increase
over time in culture. We observed no verifiable muta-
tions that displayed this pattern.
Reasoning that measuring gene expression changes
across cell lines might reveal the resistance mechanism,
we calculated the covariance of gene expression with
respect to increasing resistance. Pathway enrichment
analysis showed an enrichment for genes encoding pro-
teins involved in B-cell development. Given the role that
DNA methylation plays in B-cell lineage commitment
[28, 38], we characterized the DNA methylome of our
resistant lines. Analysis of DNA methylation changes
suggested that expression of genes regulated by the his-
tone methyltransferase complex PRC2 were altered in
the most resistant lines.
PRC2 plays a critical role in B-cell development by
repressing genes necessary for hematopoietic differentiation
Fig. 5 B-cell development principal component analysis. a Scatter plot of the principal components of the Immunological Genome Project data
and the data on resistant lines. b Heat map of the –log10(p) values for the overlap of high and low covariance genes with transcription factor
target genes
Table 1 TCF3 target gene methylation
TCF3 target Not TCF3 target
Differential methylation 208 80
No differential methylation 5086 12,370
DNA methylation data obtained from The Cancer Genome Atlas shows an
increase in differential methylation in TCF3 target genes in patients with
DLBCL who showed stable or progressive disease compared with individuals
who had complete response
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through the addition of tri-methylation to lysine 27 of his-
tone H3. During hematopoietic stem cell differentiation,
this repressive mark is lost from genes that commit
hematopoietic stem cells to differentiation [30, 31, 39]. Nu-
merous studies have shown that overexpression of, or acti-
vating mutations in, PRC2 components, particularly Ezh2,
contribute to proliferation and lymphomagenesis in DLBCL
patients [40, 41]. To evaluate how the presence of the
H3K27me3 mark is correlated with resistance, we per-
formed ChIP-seq on H3K27me3 in the parental and resist-
ant cell lines. A large fraction of promoters in the resistant
lines showed rapid and widespread H3K27me3 acquisition
followed by a gradual reduction. This pattern of rapid
H3K27 methylation followed by demethylation has been
reported in patients: loss of H3K27me3 is a predictor of
poor outcome [42]. These results suggest that PRC2 is rap-
idly activated by the DNA damage induced by mafosfamide,
which is consistent with previous literature suggesting
the PRC2 is targeted to sites of DNA damage [43, 44].
Furthermore, these results suggest that this initial re-
sponse is attenuated as cells become adapted to higher
doses of mafosfamide and the most resistant cells have
an H3K27me3 state that is similar to that of the paren-
tal cells.
The observation that H3K27me3 is rapidly gained but
then lost suggests that it may not be the only mechan-
ism leading to resistance in our setting. The removal of
H3K27me3 at many loci may lead to its replacement
with DNA methylation, a more permanent mark. It has
been suggested that histone methylation by PRC2 may
recruit Dnmt3l, an inactive homolog of DNA methyl-
transferase, resulting in the inhibition of CpG methyla-
tion [32]. The gradual removal of H3K27me3 could lead
to the replacement of Dnmt3l by its active counterparts,
Dnmt3a and Dnmt3b, resulting in an increase in DNA
methylation. In agreement with a potential coupling
between PRC2 and DNA methyltransferases, we ob-
served that genes that gained H3K27me3 early and then
lost this mark (cluster K2) showed a gradual increase in
DNA methylation. Thus, we conclude that the addition
of H3K27me3 to these loci results in the acquisition of
DNA methylation, leading to a stable, drug-resistant
epigenome.
Our analyses also indicate the involvement of B-cell
developmental regulators in the epigenetic transition to
drug resistance. Among these regulators, which include
E2a and PU.1, we believe that E2a plays a central role.
Clustering of the H3K27me3 ChIP-seq data showed that
E2a is strongly associated with genes that gain and sub-
sequently lose H3K27me3 that also gradually gain DNA
methylation. Genes with significant levels of differential
DNA methylation were also enriched in those bound by
E2a. E2a encodes two proteins, E12 and E47, that are
known to be master regulators involved in the process
of B-cell lineage commitment [33]. Principle component
analysis of gene expression from the resistant lines and
from various stages of B-cell development indicated that
the expression of E2a target genes is strongly correlated
with B-cell maturation states. In addition, the E2a locus
is repressed early in B-cell development but it becomes
transcriptionally active during B-cell commitment [45].
The central role of E2a-mediated regulation of gene ex-
pression in Burkitt’s lymphoma is made evident by the
fact that it is the fifth-most mutated gene in patients
with Burkitt’s lymphoma and all mutations affect the
DNA binding domain [46]. Inhibition of E2a expression
using small interfering RNA results in lower levels of
Cdkna1 (p21) and higher PUMA expression, impairment of
cell cycle arrest, and increased Tp53-dependent apoptosis
[47]. Our data suggest that E2a may be playing a critical
role in mediating the resistance phenotype as it appears to
be a key regulator of the response to mafosfamide.
Taken together, our results suggest that PRC2 and
known regulators of B-cell development induce epigen-
etic changes in genes encoding key hematopoietic devel-
opmental and pluripotency genes that result in the
resistant phenotype. Upon treatment with mafosfamide,
the cells we studied underwent rapid and widespread ac-
quisition of the repressive mark H3K27me3. This methy-
lation is coupled to changes in the activity of B-cell
developmental regulators, such as E2a, ultimately result-
ing in changes in transcription of genes involved in B-
cell development. As the cells became more resistant,
the H3K27me3 response was attenuated and replaced by
the more permanent mark 5-methylcytosine. We specu-
late that these changes led the Eμ-Myc cell lines to epi-
genetically transition along the B-cell developmental
axis, leading to a suppression of the apoptotic response
upon exposure to mafosfamide. Evidence for this transi-
tion is provided by our integrative analysis of Immgen
data that captures a principal component of the B-cell
developmental axis. As the cells became more resistant
to mafosfamide, they appear to move backwards along
this axis. The diminished apoptotic response of cells
with stem-like characteristics compared with that of dif-
ferentiated cells has been described in many other sys-
tems and may thus represent a general mechanism for
the acquisition of drug resistance [48, 49].
Finally, we have shown that similar mechanisms may
also occur in human lymphomas. Our analysis of sam-
ples from patients with diffuse large B-cell lymphoma
suggests that there are epigenetic differences between
patients who remain disease-free versus those who have
disease progression. Moreover, the sites of differential
methylation are significantly associated with genes that
are bound by Tcf3, the human ortholog of E2a. Thus,
our murine model may capture epigenetic resistance
mechanisms that are also present in human disease,
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suggesting that epigenetic plasticity impairs therapeutic
regimens in the clinic.
Conclusions
Our results indicate that resistance to DNA alkylating
agents in B-cell lymphoma is associated with alterations
in both CpG methylation and H3K27me3 but not with
genetic changes. We found that repressive epigenetic
markers are preferentially altered in the promoter re-
gions of genes bound by the B-cell development regula-
tor E2a, suggesting that this transcription factor plays a
key role in mediating the resistance phenotype, possibly
by suppressing apoptosis. We also showed that differen-
tial methylation of genes bound by TCF3, the human
ortholog of E2a, is associated with treatment failure in
diffuse large B-cell lymphoma patients.
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